Increased 'anaerobic' glucose metabolism is observed after traumatic brain injury (TBI) attributed to increased glycolysis. An alternative route is the pentose phosphate pathway (PPP), which generates putatively protective and reparative molecules. To compare pathways we employed microdialysis to perfuse 1,2-13 C 2 glucose into the brains of 15 TBI patients and macroscopically normal brain in six patients undergoing surgery for benign tumors, and to simultaneously collect products for nuclear magnetic resonance (NMR) analysis. 13 C enrichment for glycolytic 2,3-13 C 2 lactate was the median 5.4% (interquartile range (IQR) 4.6-7.5%) in TBI brain and 4.2% (2.4-4.4%) in 'normal' brain (P o0.01). The ratio of PPP-derived 3-13 C lactate to glycolytic 2,3-13 C 2 lactate was median 4.9% (3.6-8.2%) in TBI brain and 6.7% (6.3-8.9%) in 'normal' brain. An inverse relationship was seen for PPP-glycolytic lactate ratio versus P bt O 2 (r = − 0.5, P = 0.04) in TBI brain. Thus, glycolytic lactate production was significantly greater in TBI than 'normal' brain. Several TBI patients exhibited PPP-lactate elevation above the 'normal' range. There was proportionally greater PPP-derived lactate production with decreasing P bt O 2 . The study raises questions about the roles of the PPP and glycolysis after TBI, and whether they can be manipulated to achieve a better outcome. This study is the first direct comparison of glycolysis and PPP in human brain.
INTRODUCTION
An increase in the proportion of glucose undergoing 'anaerobic' (non-oxygen consuming) metabolism is observed after traumatic brain injury (TBI). [1] [2] [3] This has been postulated to provide the energy in the form of adenosine triphosphate (ATP), produced via glycolysis, needed to restore ionic and neurochemical gradients, which become disturbed after TBI. 4, 5 Upregulation of the pentose phosphate pathway (PPP) has also been suggested as a possible contributor to increased anaerobic glucose metabolism after TBI, based on rat models, and indirect (arteriovenous-jugular difference) studies in human patients. [6] [7] [8] Glycolysis consists of the Embden-Meyerhof pathway from glucose to pyruvate, which does not use oxygen, and generates 2 moles of ATP per mole of glucose. Pyruvate can then be metabolized via the mitochondrial tricarboxylic acid cycle (TCA) cycle coupled to mitochondrial electron transport chains, which utilize oxygen in oxidative phosphorylation. The theoretical overall yield is 36 moles of ATP per mole of glucose. Alternatively, pyruvate can be converted to lactate, which recycles NADH (reduced nicotinamide-adenine dinucleotide) to NAD + , enabling further glucose molecules to be processed by glycolysis.
The PPP, also termed the hexose monophosphate shunt, is a biosynthetic pathway that constitutes a complex detour bypassing some of the steps of glycolysis in the metabolism of glucose. The key enzyme for the PPP, glucose-6-phosphate dehydrogenase, which is responsible for the rate-limiting step, is present in most tissues and cell types, and is regarded as a 'housekeeping' enzyme. 9, 10 The PPP does not consume or produce ATP and does not require molecular oxygen. In the early 'oxidative phase' of the PPP, during which the first carbon of the glucose skeleton is lost as carbon dioxide, nicotinamide adenine dinucleotide phosphate (NADP + ) is converted to NADPH. The latter is a reducing agent that participates in reductive biosynthetic reactions, such as lipid and steroid synthesis, and in the production of the reduced form of glutathione and thioredoxin. Glutathione and thioredoxin are cofactors for glutathione peroxidase enzymes and peroxiredoxins respectively, both of which scavenge hydroperoxides, thereby combatting oxidative stress. Among the many intermediates of the later 'non-oxidative' phase of the PPP is ribose 5-phosphate, used for nucleic acid synthesis. Hence, the proportion of glucose metabolized via the PPP is greatest in tissues with high lipid-and steroid-synthetic roles (for example, liver and lactating mammary glands), also in cells with a high oxidative load (for example, red blood cells), and is thought to be one of the mechanisms supporting high cell proliferation rates in cancer. 10 PPP activity after TBI has been postulated as having a protective role, promoting synthesis of nucleic acids and fatty acids for tissue repair and combatting the oxidative stress that results from injured cells. 6, 11 Our aim was to evaluate glycolysis and the PPP as routes of glucose metabolism, directly in TBI patients' brains. Our novel approach was to perfuse the brain using a microdialysis catheter with 1,2-13 C 2 glucose and measure the ensuing labeling patterns in lactate collected in the emerging microdialysates by analyzing them using high-resolution nuclear magnetic resonance (NMR) spectroscopy. For comparison, we also carried out the same technique in the 'normal' brain, and in muscle as a non-CNS tissue. The present study is the first direct comparison of glucose metabolism via glycolysis and PPP in human brain.
MATERIALS AND METHODS Patients
The Cambridge Central Local Research Ethics Committee approved this study. Informed consent was obtained from all participants in the control 'normal' brain and muscle groups and assent from the relatives of those patients who had suffered a TBI. The study was carried out in conformation with the spirit and the letter of the Declaration of Helsinki.
TBI brain microdialysis patients. The TBI patients were defined as those experiencing cranial trauma with consistent computed tomography (CT) scan findings and requiring invasive intracranial monitoring as part of their clinical management. Patients were managed according to local TBImanagement protocols, which include endotracheal intubation, ventilation, sedation, and muscular paralysis. 12 Control 'normal' brain microdialysis patients. Patients undergoing a craniotomy for the resection of a benign lesion whereby a microdialysis catheter could be safely placed into radiographically normal brain were selected as control subjects. The microdialysis catheter was placed via the craniotomy and tunneled under the scalp. The control patients were awake for the duration of microdialysis perfusion.
Muscle microdialysis patients. Patients undergoing resections of acoustic neuromas that required thigh fat and fascia harvesting for dural closure were recruited for studying muscle, for comparison with the brain. During the procedure to harvest fat and fascia, a microdialysis catheter was placed under direct vision into quadriceps muscle. The muscle microdialysis subjects were under general anesthesia for the duration of the microdialysis perfusion, which was performed at the same time of day for each patient minimizing the effect of diurnal variation.
Microdialysis Technique
CMA 71 microdialysis catheters (membrane length 10 mm, nominal molecular weight cutoff 100 kDa) (M Dialysis AB, Stockholm, Sweden) were placed either via a triple lumen cranial access device (Technicam, Newton Abbot, UK) or during a craniotomy for a traumatic lesion, along with an intracranial pressure monitor (Codman, Raynham, MA, USA) and a Licox brain tissue oxygen sensor (GMS, Kiel-Mielkendorf, Germany) into the frontal lobe. For TBI patients with a diffuse injury, the right frontal region was chosen; if there was greater injury to one hemisphere rather than the other, the most injured side was chosen. The catheter was neither placed within nor immediately adjacent to the lesion itself. The CMA 71 catheters were used for control 'normal' brain subjects and were placed via the cranial opening at the end of their neurosurgical procedure. CMA 60 catheters (membrane length 30 mm, nominal molecular weight cutoff 20 kDa) were used for muscle subjects and placed under direct vision into right quadriceps muscle following fat and fascia harvesting under general anesthesia.
Catheters in the TBI patients and the normal brain control subjects were perfused with CNS Perfusion Fluid (M Dialysis, AB), composed of NaCl (147 mmol/L), KCl (2.7 mmol/L), CaCl 2 (1.2 mmol/L), and MgCl 2 (0.85 mmol/L) in water, supplemented with 4 mmol/L 1,2-13 C 2 glucose (see below for details). Muscle microdialysis catheters were perfused with T1 Perfusion Fluid (M Dialysis AB), composed of NaCl (147 mmol/L), KCl (4 mmol/L), and CaCl 2 (2.3 mmol/L) in water, supplemented with 4 mmol/L 1,2-13 C 2 glucose. The concentration (4 mmol/L) of the 13 C-labeled substrate was chosen to be within the range found in brain and muscle microdialysates in unlabeled studies, to minimize perturbation. 13-15 1,2-13 C 2 glucose (isotopic enrichment 99%, chemical purity 99%) was obtained from Cambridge Isotope Laboratories (Tewksbury, MA, USA) and was formulated in CNS perfusion fluid or T1 perfusion fluid by the Manufacturing Unit, Department of Pharmacy, Ipswich Hospital NHS Trust (Ipswich, UK), who then tested the formulations to verify purity, sterility, freedom from endotoxins, and absence of pyrogenicity, to comply with current regulations, before releasing them for use in patients. Microdialysate collection vials from the TBI patients were changed hourly and analyzed at the bedside using an ISCUS analyzer (M Dialysis AB) employing enzymatic colorimetric assays for glucose, lactate, pyruvate, glutamate, and glycerol. Microdialysate vials from the 'normal' brain and from muscle were also analyzed with the ISCUS analyzer at 4-and 2-hour intervals, respectively. Intracranial pressure, cerebral perfusion pressure, and brain tissue oxygen tension (P bt O 2 ) data from TBI patients were recorded at the bedside using ICM+ software (ICM+, University of Cambridge, UK). Microdialysate samples were stored at 4°C (or at − 80°C if storage for longer than a few days was necessary) before the NMR analysis.
NMR Analysis
Brain microdialysate samples were pooled into 24-hour periods for each individual patient. For NMR analysis, 20 μL of deuterium oxide (D 2 O) and 50 μL internal reference standard from a stock solution of 24.0 mmol/L 3-(trimethylsilyl)-1-propanesulfonic acid sodium salt (also termed 2,2dimethyl-2-silapentane-5-sulfonate sodium salt or 4,4-dimethyl-4-silapentane-1-sulfonate sodium salt; DSS; Sigma-Aldrich, Poole, Dorset, UK) in the CNS perfusion fluid (M Dialysis) was added to 180 μL of the pooled microdialysate sample. Muscle microdialysate samples were pooled into 8hour periods. Twenty microliters of D 2 O and 70 microliters from a stock solution of 2.84 mmol/L DSS was added to 120 μL of the pooled microdialysate sample. Pooled samples, after addition of D 2 O and DSS, were stored at − 80°. For NMR analysis, samples were transferred into 3 mm NMR tubes (Hilgenberg GmbH, Malsfeld, Germany). 13 C and 1 H NMR spectra were acquired on a Bruker Avance III HD 500 MHz spectrometer (Bruker BioSpin GmbH, Karlsruhe, Germany) with a dual 1 H/ 13 C cryoprobe (CP DUL500C/H, Bruker BioSpin GmbH). 13 C and 1 H NMR spectra were acquired and processed using the TopSpin software (Bruker GmbH). 1 H spectra were acquired using the pulse program noesypr1d, a 1D Nuclear Overhauser Effect Spectroscopy (NOESY) experiment using presaturation to suppress the water signal. Acquisition parameters included 32 scans with a d1 (relaxation delay) of 2 seconds. 13 C spectra were acquired using the pulse program zgpg30, which has a 30degree flip angle on the carbon channel, with a d1 of 3 seconds, using 4,096 (4 k) scans and digitizing 64 K points. Power-gated broadband 1 H decoupling is achieved using the 'WALTZ-16' supercycle. The receiver gain is set to a constant value in each experiment. Metabolite signals in the samples were identified by comparison of their chemical shifts (p.p.m., reference DSS) to values from NMR databases (BMRB-Biological Magnetic Resonance Bank, University of Wisconsin 16 ; HMDB-Human Metabolome Database, Genome Alberta 17 ) and to those of our own standards. To confirm the identity of peaks, in selected cases, 1 H-13 C heteronuclear single quantum correlation spectra were acquired on standards and patients' microdialysate samples.
To enable quantification of the signals in the 13 C and 1 H one-dimensional spectra, calibration was carried out with a series of known concentrations of standards including lactate, 3-13 C lactate, glucose, 1,2-13 C 2 glucose, and glutamine (from Sigma-Aldrich and Cambridge Isotope Laboratories). These standards were prepared in CNS perfusion fluid with the same fixed concentration of D 2 O and DSS as for the preparation of brain microdialysate samples (see above) as an internal standard and run under identical NMR conditions to the pooled microdialysates. Peak areas for DSS, glucose, lactate, and glutamine signals identified on the 13 C and 1 H spectra were determined using combined Gaussian and Lorentzian line-shape fitting. Peak areas relative to the DSS internal standard were used with reference to calibration curves for each signal derived from standards (see above) of known concentrations, which showed linear relationships between peak areas (ratio to DSS internal standard) and concentrations. Fractional enrichment (%) is defined as 100 × [ 13 C]/([ 13 C]+[ 12 C]) where square brackets indicate concentrations of the relevant species. [ 13 C] was determined from the 13 C NMR spectra and [ 12 C] from the 1 H spectra, using the calibration method above. The natural abundance of 13 C is 1.1% of all carbon atoms, and 13 C results presented for lactate (see Results section) were expressed after subtracting this natural background from the 13 C singlet signals. 13 C doublet signals were not background-subtracted because the probability of two 13 C atoms occurring next to each other naturally is 0.01%.
Interpretation of the NMR results was based on biosynthetic pathways summarized schematically in Figure 1 , which shows the lactate-labeling patterns corresponding to glycolysis, which produces 2,3-13 C 2 lactate, and the PPP, which produces 3-13 C lactate.
Statistical Analysis
Statistical analyses performed using SPSS21 for Mac (IBM SPSS Statistics, NY, USA) included non-parametric tests (Mann-Whitney U-test and Kruskal-Wallis one-way analysis of variance) with a preselected P value of 0.05 for statistical significance. Results are presented as the median values with the interquartile range (IQR) given in parentheses. Relationships between P bt O 2 and the 13 C labeling results were explored using linear regression, with Pearson's correlation coefficient r and analysis of variance P values.
RESULTS

Demography
Fifteen severe TBI patients (10 male and 5 female patients) aged 16-59 years (median 27 years) were studied using 1,2-13 C 2 glucose (4 mmol/L) perfusion via the microdialysis catheter, with simultaneous collection of microdialysates for NMR analysis. For comparison, macroscopically normal-appearing brain was studied using the same 13 C-labeled microdialysis method in six patients (age range 59-73 years; three male and three female patients) undergoing surgery for benign brain tumors. For a non-CNS tissue comparison, thigh (quadriceps) muscle was similarly studied in four patients (age range 20-61 years; three male and one female patients) who underwent surgery for acoustic neuroma resection. A further seven patients (two 'normal' brain and five muscle) were studied by microdialysis but with plain unsupplemented perfusion fluid without 1,2-13 C 2 glucose. The 15 TBI patients who received 1,2-13 C 2 glucose (see above) were also studied for a baseline period with plain unsupplemented perfusion fluid (without 1,2-13 C 2 glucose). Demographic details of all patients are presented in Supplementary Table 1 .
Baseline Results Compared with 1,2-13 C 2 Glucose Perfusion Period Microdialysate measurements (using the ISCUS analyzer) of glucose, lactate, pyruvate, glutamate, and glycerol are shown in Figure 2 . These were acquired in the 15 TBI patients during periods when the microdialysis catheter was perfused with plain unsupplemented CNS perfusion fluid and also during the 24-hour period of perfusion with 1,2-13 C 2 glucose (4 mmol/L). In 'normal' brain, the ISCUS analysis was performed for two patients who received plain unsupplemented perfusion fluid and for six patients who received 24-hour perfusion with 1,2-13 C 2 glucose (4 mmol/L). In muscle, the ISCUS analysis was performed for five patients who received plain unsupplemented perfusion fluid, and for four patients who received 8-hour perfusion with 1,2-13 C 2 glucose (4 mmol/L). The 8-hour period for muscle was necessitated because of clinical practicalities of limb movement-microdialysis was limited to periods during the acoustic neuroma surgery.
Significant increases (Po0.05) in microdialysate glucose concentration (measured on the ISCUS analyzer) between baseline (unsupplemented) and the 1,2-13 C 2 glucose perfusion period were seen for all three groups, as follows (medians): TBI brain (from 1.0 to 3.8 mmol/L), 'normal' brain (from 1.9 to 3.9 mmol/L), and muscle (from 2.8 to 5.3 mmol/L). The only other statistically significant, but not thought to be biologically significant, changes in ISCUS results 1,2-13 C 2 glucose metabolism in TBI I Jalloh et al between baseline and the 1,2-13 C 2 glucose perfusion period were for lactate/pyruvate ratio in TBI brain (from 22.2 to 24.8), for glycerol in TBI brain (from 52.0 to 69.6 μmol/L), and for glutamate in TBI brain (from 3.4 to 4.4 μmol/L) and muscle (from 7.9 to 29.7 μmol/L). Concentrations of 1,2-13 C 2 glucose (median and IQR) measured with 13 C NMR in the microdialysates from TBI brain (24-hour perfusion period), normal brain (24-hour perfusion period), and muscle (8hour perfusion period) were, respectively, 2.14 (1.45-2.43), 0.93 (0.83-1.83), and 0.95 (0.59-1.25) mmol/L, with TBI significantly different from normal brain (P = 0.008) or muscle (P = 0.016).
Throughout the 24-hour period, during which the cerebral microdialysis catheter was perfused with 1,2-13 C 2 glucose, the median serum glucose concentration measured in TBI patients was 7.3 mmol/L and all values were within the range 4-12 mmol/L except for one time point in patient 11 in which glucose was 1 mmol/L ( Supplementary Figure 1) . The median serum lactate concentration was 1.1 mmol/L (min 0.7, max 3.0 mmol/L; Supplementary Figure 1 ).
NMR Results for Lactate Production by Glycolysis and PPP, and Relationship with Brain Tissue Oxygen
Illustrative examples of 13 C NMR spectra of the microdialysates are shown in Figure 3 . As a result of 1,2-13 C 2 glucose perfusion, TBI brain and 'normal' brain microdialysates included a clearly visible doublet (red stars in expansion of 13 C spectra) for the lactate C3 methyl group, and likewise a double for lactate C2, indicating glycolysis-derived 2,3-13 C 2 lactate, and a smaller C3 singlet (green stars in expansion of 13 C spectra) representing PPP-derived 3-13 C lactate plus endogenous lactate. Qualitatively similar-appearing Figure 2 . ISCUS clinical microdialysis analyzer measurements: at baseline (light gray bars) with plain unsupplemented perfusion fluid and during 24-hour perfusion (brain: TBI or normal) or 8-hour perfusion (muscle) with 1,2-13 C 2 glucose (4 mmol/L; dark gray bars). LP ratio is the lactate/pyruvate ratio. *P o0.05 (Mann-Whitney) for baseline versus perfusion with 1,2-13 C 2 glucose. Box and whisker plots represent pooled data. Numbers of patients with baseline (unsupplemented) measurements were 15 TBI, 2 'normal' brain, and 5 muscle. Numbers of patients who received 1,2-13 C 2 glucose were 15 TBI, 6 'normal' brain, and 4 muscle. 'Normal' brain was macroscopically normal-appearing brain in patients who underwent surgery for benign brain tumors. Muscle was leg quadriceps in patients undergoing acoustic neuroma resection surgery. spectra were seen for muscle microdialysates resulting from 1,2-13 C 2 glucose perfusion. Unlabeled TBI microdialysates (with plain unsupplemented perfusion fluid) showed singlets for endogenous lactate C3 and C2 (Figure 3 ).
Natural abundance of 13 C was assumed to be 1.1%, and 13 C fractional enrichment values for lactate were expressed after subtracting this naturally occurring 13 C background from the 13 C singlet signals. In TBI brain microdialysates, 13 C fractional enrichment (%) in 2,3-13 C 2 lactate, indicative of glycolysis, was median 5.4% (IQR 4.6-7.5%) measured using the C3 doublet and this was significantly greater than in 'normal' brain ( Figure 4) . Fractional enrichment was based on quantification of the lactate C3 doublet signal ( 13 C spectrum) to measure 13 C at the C3 position and the lactate methyl protons (attached to C3) triplet signal ( 1 H spectrum) to quantify 12 C at the C3 position. Similar 13 C fractional enrichment to that of lactate C3 doublet was obtained using the lactate C2 doublet, as expected ( Figure 4 ). In muscle, 13 C fractional enrichment in 2,3-13 C 2 lactate was lower than in TBI and 'normal' brain ( Figure 4) .
On the basis of the lactate C3 methyl group, 13 C fractional enrichment (%) in 3-13 C lactate indicative of the PPP in TBI brain microdialysates was median 0.24% (IQR 0.17-0.61%; Figure 4 ), which was thus much less than the 13 C fractional enrichment in glycolytic 2,3-13 C 2 lactate (above). The ratio in TBI brain microdialysates of PPP-derived 3-13 C lactate to glycolytic 2,3-13 C 2 lactate was median 4.9% (IQR 3.6-8.2%) ( Figure 4 ). Four of the fifteen TBI patients exhibited ratios of PPP-derived to glycolytic lactate (11.4, 11.5, 11.9, and 14.0%) that were greater than the range observed in the present study in normal brain (min 5.9, max 10.4%).
In muscle, microdialysis perfusion with 1,2-13 C 2 glucose (4 mmol/L, for 8 hours) resulted in lactate C3 doublet and C2 doublet, indicating glycolytic 2,3-13 C 2 lactate, with 13 C enrichment at the C3 median 1.2% (range 1.0-1.4%). However, there was no 13 C enrichment above background natural abundance for lactate C3 singlet; therefore, PPP production of lactate was not detected in muscle.
The concentration of 2,3-13 C 2 lactate (indicative of glycolysis) showed a nonsignificant inverse trend (r = − 0.4, P = 0.1) with brain tissue oxygen concentrations (PbtO 2 expressed in mm Hg) measured in the vicinity of the microdialysis catheter in TBI brain. A significant inverse correlation (r = − 0.5, P = 0.04) was seen for the ratio of PPP-lactate to glycolytic lactate versus P bt O 2 ( Figure 5 ). Local tissue oxygen concentration was not measured in normal brain or muscle.
Five TBI patients had a second 24-hour period of 1,2-13 C 2 glucose (4 mmol/L) microdialysis perfusion. There were no significant differences in the production of glycolytic lactate or PPP-derived lactate between these two time periods.
DISCUSSION
This study has shown that 1,2-13 C 2 glucose infusion via the microdialysis catheter results in 13 C-labeling in lactate (Figure 3 ) in the emerging microdialysates, enabling us to compare glycolysis and PPP as routes by which lactate is derived. This is the first time this comparison has been performed directly in human brain. 
Glucose Metabolism via Glycolysis and the Pentose Phosphate Pathway
Clear evidence for glycolysis being the main route of lactate production from glucose, as expected, was seen as diagnostic doublet signals for both C3 and C2 of lactate ( Figure 3 ) indicating 2,3-13 C 2 lactate, a hallmark of the pathway (Figure 1) . These doublets were seen for all patients, in TBI brain, 'normal' brain and muscle. This is in accord with the recognized glycolysis pathway consisting of the Embden-Meyerhof pathway from glucose to pyruvate, followed by conversion to lactate by the action of lactate dehydrogenase (Figure 1 ). This 13 C enrichment was significantly higher in the TBI brain, suggesting greater glycolytic activity than in 'normal' brain and muscle. The doublet signals provide a distinctive signature that in effect avoids the issue of natural abundance 13 C background (1% of all carbon atoms) because the probability of two endogenous 13 C atoms occurring next to each other naturally is 0.01%.
The PPP loses the first carbon of 1,2-13 C 2 glucose as carbon dioxide and thus gives rise to 3-13 C lactate with a singlet signal for C3 ( Figure 1) . Whereas 13 C singlet signals for lactate C3 were clearly visible in all patients' microdialysates ( Figure 3) , these were smaller than the C3 doublet. Furthermore, it emerged that much of the C3 singlet signal intensity (peak area) was because of endogenous natural abundance 13 C. Small 13 C fractional enrichments for lactate C3 singlet above this background were seen in microdialysates from TBI brain and 'normal' brain, indicating PPPderived lactate, but were negligible in muscle. Although there was no statistically significant difference in 13 C fractional enrichment for lactate C3 between 'normal' brain and TBI brain, the higher upper range of the latter suggests that in certain TBI individuals lactate production via the PPP is elevated above that in 'normal' brain. In the four TBI patients with the most elevated PPP lactate, the ratio (%) of PPP lactate to glycolytic lactate was 11.4-14.0%.
Our finding of increased PPP activity in some patients as a result of brain injury is supported by experimental studies. In rat models relevant to TBI, Bartnik et al 6,7 infused 1,2-13 C 2 glucose intravenously after fluid percussion injury and cortical contusion injury, and performed NMR analysis of brain tissue extracts. 6, 7 They found an increase in the proportion of 3-13 C lactate (indicative of PPP) relative to 2,3-13 C 2 lactate (indicative of glycolysis) in brain-injured rats compared with control rats, although with glycolysis remaining dominant. In humans, Dusick et al 8 infused 1,2-13 C 2 glucose intravenously, with 13 C labeling in lactate assessed by . Microdialysate NMR measurements of 13 C labeling: results from perfusion for 24-hour-(brain: TBI or 'normal') or 8-hour perfusion (muscle) with 1,2-13 C 2 glucose (4 mmol/L). Red asterisks denote P o0.01 for TBI versus 'normal' brain (Mann-Whitney); other comparisons asterisked in black denote P o0.05. Individual data points are shown by × symbols. Number of patients: 15 TBI, 6 'normal' brain, and 4 muscle. arteriovenous-jugular difference. 8 This study in TBI patients and controls, although it did not sample the brain directly and could only yield information on brain lactate labeling during periods when the brain was a net exporter of lactate into the vasculature, led to similar conclusions to the rat studies above.
Significance of the PPP The PPP is a complex biosynthetic network generating many other species besides lactate (Figure 1 ) and the balance between these species can potentially shift depending on the local biology and pathology. Some PPP-derived species are potentially reparative, for example, ribose (for nucleic acid synthesis) and NADPH (to provide reducing equivalents for fatty acid synthesis), and neuroprotective for example, NADPH, used for producing the reduced form of glutathione and thioredoxin, which are cofactors for glutathione peroxidases and peroxiredoxins, respectively, enzymes that combat oxidative stress. Accordingly, Herrero-Mendez et al 18 demonstrated that if one of the key regulatory enzymes of glycolysis, phosphofructokinase, is activated in neurons so that more glucose is funneled through glycolysis at the expense of the PPP, apoptosis soon ensues because of oxidative stress. 18 The PPP, which does not involve molecular oxygen and does not generate ATP, can thus be regarded as sacrificing some of the cells' supply of glucose molecules, which might otherwise have been used for ATP synthesis via glycolysis and the TCA cycle, for the sake of generating more reducing power (NADPH) and the ability to protect, repair, or build cells.
NADPH is involved in many other biochemical reactions, for example, NADPH is a cofactor for NADPH oxidase and nitric oxide synthase and, if these become dysregulated, oxidative stress may ensue, with adverse consequences. Zuurbier et al 19 reported that inhibition of the so-called 'oxidative' phase of the PPP (the early steps of the PPP responsible for NADPH production), by means of administering 6-aminonicotinamide, was cardioprotective in an ischemia-reperfusion rat heart model. 19 Interestingly, when Tyson et al 20 administered 6-aminonicotinamide to inhibit the PPP in rats in a study of brain using intravenous 2-13 C glucose as the substrate, they found that despite achieving PPP inhibition, evidenced by a build-up of 6-phosphogluconate, there appeared to be a feedback effect of PPP inhibition on glycolysis, such that both pathways decreased in a constant ratio. 20 
Role of Brain Tissue Oxygen Concentration in Brain Metabolism
In the literature, 'hyperglycolysis' and the elevation of lactate production in the injured brain have been attributed to hypoxia and/or mitochondrial dysfunction, although the exact nature of the latter remains unclear. In a combined positron emission tomography (oxygen-15 and fluorodeoxyglucose (18 F)) and microdialysis study, Vespa et al 2 reported that 'metabolic crisis' (defined as lactate/pyruvate ratio 440) occurred in 7 out of 19 TBI patients studied, although only one case showed regional ischemia judged by positron emission tomography. 2 In a microdialysis study of 24 TBI patients in conjunction with P bt O 2 measurement and perfusion CT, Sala et al 21 concluded that the majority of lactate production was 'glycolytic' (rather than hypoxic), albeit without evidence from carbon labeling. 21 In the present study, we measured P bt O 2 alongside the microdialysis catheter in the TBI patients and found that there was a nonsignificant trend towards greater glycolytically generated 2,3-13 C 2 lactate with decreasing PbtO 2 . It is important to note that there were only three cases that could be described as hypoxic (defined as P bt O 2 o20 mm Hg), and the remaining 14 data points ranged from 22 to 43 mm Hg. Interestingly, the ratio of PPP-derived lactate to glycolytic lactate showed a significant inverse correlation with P bt O 2 (r = − 0.5, P = 0.04; Figure 5 ). Thus, although PPP-derived lactate was always much less than glycolytic lactate, the balance between the two appeared to shift towards the PPP with lower P bt O 2 . Similar to glycolysis, the PPP does not utilize oxygen. Studies in adult rats and in brain slices have also suggested that hypoxia increases the PPP. 22 In contrast, Brekke et al 23 found evidence for a decrease in PPP in neonatal rats after hypoxic-ischemic injury, which the authors discussed as paradoxical. 23 Moreover, they postulated that the apparent inability to upregulate the PPP in this situation might render the neonatal rats vulnerable. An analogous situation might conceivably exist in human TBI, whereby low ability to upregulate the PPP might result Figure 5 . Relationships in TBI brain for glycolytic lactate and pentose phosphate pathway (PPP)-derived lactate versus P bt O 2 . Concentrations of glycolytic 2,3-13 C 2 lactate (upper panel) and PPP-derived 3-13 C lactate (middle panel) plotted versus P bt O 2 . Lower panel: ratio (%) of PPP-derived 3-13 C lactate to glycolytic 2,3-13 C 2 lactate, plotted versus P bt O 2 . Each data point represents the results of NMR analysis of the combined contents of 24 × 1 hours of microdialysate collection vials from one microdialysis catheter, plotted against the corresponding P bt O 2 concentration expressed in mm Hg, measured using a Licox oxygen probe placed alongside the microdialysis catheter in the brain. Lines are fitted by linear regression (statistics shown are Pearson's correlation coefficient r and analysis of variance P value). Data are from 13 TBI patients. Four of these thirteen had a second period of monitoring, making 17 data points in total for each correlation.
in increased risk of damage in those individuals' brain tissue (either globally or locally). Therapeutic upregulation of the PPP in this context might be beneficial. Apart from hypoxia (mentioned above), a few other upregulators of the PPP have been identified. Insulin has been shown to increase the expression of glucose-6phosphate dehydrogenase mRNA in primary rat hepatocytes. 24 Dehydroascorbate, the oxidized form of vitamin C, has been shown to stimulate the activity of several PPP enzymes, increase glutathione levels, and inhibit hydrogen peroxideinduced changes in mitochondrial transmembrane potential in Jurkat cells (a cancer cell line). 25 Although these two latter studies were not performed in the brain, they nevertheless illustrate the principle that the PPP can be deliberately upregulated with measurable biochemical and biological effects.
Significance of Lactate in the Brain
Lactate has been conventionally regarded as a waste product of glucose metabolism, although a more recent idea is that it can act as a brain fuel-neurons take up lactate (produced from glucose by glia), metabolize lactate to pyruvate, which is transported into the mitochondria and converted to acetyl CoA, which enters the tricarboxylic acid (TCA) cycle. This has become known as the astrocyte-neuron lactate shuttle hypothesis. 26 Animal studies have provided evidence for brain utilization of intravenously administered 3-13 C lactate via the TCA cycle. 27 In the human brain, direct evidence for utilization of lactate was first obtained in a cerebral microdialysis study in TBI patients. 28 In the latter study, administration of 3-13 C lactate via the microdialysis catheter, and simultaneous collection of the emerging microdialysates, with 13 C NMR analysis, revealed 13 C labeling in glutamine consistent with lactate utilization via the TCA cycle. 28 Recently, an intravenous lactate supplementation study in TBI patients revealed evidence for a beneficial effect judged by surrogate end points. 29 Studies of brain microdialysates (without supplementation) in 223 patients show a statistical association between high extracellular lactate and unfavorable outcome. 30 Taken together, available evidence suggests that where neurons are too damaged to utilize the lactate produced from glucose by astrocytes, that is, uncoupling of neuronal and glial metabolism, high extracellular levels of lactate would accumulate, explaining one potential mechanism behind the association between high extracellular lactate and poor outcome.
Fate of Lactate
Regarding the possible fate of labeled lactate produced from 1,2-13 C 2 glucose, a likely scenario is that some of the labeled lactate is processed via the TCA cycle, and some of it exported into the bloodstream. Because we were microdosing the brain with 1,2-13 C 2 glucose locally via the microdialysis catheter, it seemed highly unlikely that any of the ensuing doubly labeled lactate would have been detectable in the bloodstream, given the inevitable dilution both with endogenous unlabeled lactate and with the volume of blood; therefore, 13 C NMR analyses of blood were not performed.
Previously, using 3-13 C lactate as the substrate, we detected singly labeled glutamine (and/or glutamate) in TBI brain microdialysates, indicating the utilization of lactate via the TCA cycle. 28 In the present study, if 2,3-13 C 2 lactate (produced from the substrate 1,2-13 C 2 glucose) entered the TCA cycle in brain cells, this would in theory have resulted in doublets in the 13 C NMR spectra, because of 4,5-13 C 2 glutamine and 2,3-13 C 2 glutamine (and/or glutamate in each case) on the first turn of the cycle, and, on the second turn, doublets because of 1,2 13 C 2 glutamine and a singlet because of 3-13 C glutamine. 23, 31 Experimental models of brain injury in rodents, using 1,2-13 C 2 glucose as the substrate, with analysis of brain tissue extracts representing total intracellular and extracellular molecules, confirm double labeling in glutamate and glutamine. 6, 7, 31 In our present study, small singlet signals, but not doublets, corresponding to glutamine were seen in the 13 C NMR spectra of some of the microdialysates from 'normal' brain (4/6 patients) and TBI (2/15 patients), verified by 2D NMR methods, including 1 H-13 C heteronuclear single quantum correlation ( Supplementary Figure 2) . In theory, pyruvate cycling, 32 which breaks the 13 C-13 C bond might explain the glutamine singlets. In addition, in theory, PPP-derived 3-13 C lactate might enter the TCA cycle forming singly labeled glutamine (and/or glutamate), although accompanied by doubly labeled glutamine from glycolytic 2,3-13 C 2 lactate, as found in vitro by Brekke et al. 33 However, in the present study, quantification of the small glutamine singlets revealed no significant 13 C enrichment above natural abundance.
Microdialysis only samples the extracellular compartment and therefore cannot measure the intracellular distribution of 13 C. Even so, our 13 C-labeled microdialysis method provides a useful means for measuring 'early' glucose metabolism (glycolysis and PPP) as sufficient labeled lactate is exported into the extracellular compartment to allow detection. However, in the subsequent metabolism of lactate, the downstream dilution of 13 C label with endogenous unlabeled intermediates probably explains why we did not observe significant 13 C enrichment of extracellular metabolites derived from the TCA cycle. In our previous study, when 3-13 C lactate (4 mmol/L) or 2-13 C acetate (4 mmol/L) was perfused via the microdialysis catheter in the TBI brain, labeling in glutamine consistent with TCA cycle was seen in the emerging microdialysates. 28 However, in the same study, perfusion with 1-13 C glucose (2 mmol/L) resulted in negligible labeling in glutamine, consistent with the present study.
Strengths and Limitations
This 13 C-labeled microdialysis method, performed in parallel with local brain tissue oxygen measurement, provides a method of measuring glycolytic conversion of glucose into lactate and at the same time distinguishing hypoxic from non-hypoxic glycolysis, as well as evaluating the contribution of the PPP. Even though our evidence indicates a minor PPP-derived lactate (3-13 C lactate), it must be remembered that the PPP is a complex network of biosynthetic reactions (Figure 1) and it is conceivable that if heavy recycling is operating within the PPP, less lactate might emerge, although with elevated production of NADPH and intermediates utilized in neuroprotection and repair of cells.
The strategy of double labeling (using 1,2-13 C 2 glucose as the substrate) provides a characteristic signature that appears in glycolytic lactate (2,3-13 C 2 lactate) showing that the 13 C-13 C covalent bond stays intact. Moreover, the doublet signal is essentially free from endogenous lactate because the probability of two 13 C atoms being adjacent to each other naturally is 0.01%. Similar to all cerebral microdialyses, the 13 C-labeled microdialysis method is invasive, so is only suitable for severe TBI patients or those requiring brain surgery (for example, for tumors), and it is a focal technique. This 13 C-labeling method has the potential to be a useful adjunct to existing methodologies of positron emission tomography and unlabeled microdialysis in monitoring and studying TBI patients. The 13 C-labeled microdialysis method does not involve disruption of the patient's standard medical care on the neurocritical care unit and does not involve radioactivity or moving the patient to a scanner. The 1,2-13 C 2 glucose microdialysis method is reasonably inexpensive and convenient to perform because 1 or 2 g of the labeled material are enough to formulate enough perfusion fluid for multiple patients, and the formulation can be stored in individual sterile ready-to-use sealed glass vials in a refrigerator. The concentration (4 mmol/L) of 1,2-13 C 2 glucose administered via microdialysis locally into the brain corresponds to the upper end of the 'normal' range found in brain extracellular fluid. 13 Whereas conventional microdialysis performed with unsupplemented perfusion fluid allows us to measure endogenous extracellular lactate, the unsupplemented method cannot inherently distinguish between 'old' lactate and recently synthesized lactate. An advantage of the 1,2-13 C 2 glucose microdialysis method is that it enables the measurement of labeled lactate production within a known timeframe-at present this is 24 hours because of current practical NMR considerations (see below).
A current limitation to our 13 C-labeled microdialysis method is the amount of material necessary for performing NMR analysis. We have combined brain microdialysates for a 24-hour period for each patient to facilitate 13 C NMR spectroscopy within a convenient acquisition time on the spectrometer. Our Bruker Avance 500 MHz spectrometer is equipped with a cryoprobe, as used in the present study and in our previous study, 28 which is more sensitive than non-cryo probe technology. Even so, the practical limit with our present equipment limits us in terms of how short a time frame we can analyze in terms of microdialysis perfusion. Having better time resolution for the microdialysis labeling results would be useful from a biochemical perspective allowing time course evaluation. 1,2-13 C 2 glucose microdialysis may have future potential for metabolic kinetic modeling of local glucose consumption rates and glycolytic-and PPP-production rates of lactate. Commercially available NMR microcryoprobes, which take smaller volumes, may be useful in future. Analysis with mass spectrometry might also be useful in future, enabling smaller volumes to be analyzed, although at the expense of at least some of the detailed information on precise intramolecular position of label.
CONCLUSION
Here we have shown that 13 C-labeled microdialysis can be used to interrogate glucose metabolism via glycolysis and the PPP. The major pathway, glycolytic lactate production, was significantly greater in the TBI brain than in the normal brain. The minor pathway, PPP-derived lactate production, was statistically not significantly different in the TBI brain than in normal brain. However, several of the TBI individuals showed PPP-derived lactate elevation above the range observed in the normal brain. There was a shift in glucose metabolism from glycolysis to PPP with decreasing brain tissue oxygen concentrations. The findings raise interesting questions about the roles of the PPP and glycolysis after TBI, and whether they can be manipulated to enhance the potentially reparative and antioxidant role of the PPP and achieve a better outcome for the patient. The 13 C methodology developed here provides a means of distinguishing recently synthesized lactate and its biosynthetic origin, and at the same time measuring local oxygen tension alongside. 13 C-labeled microdialysis with 1,2-13 C 2 glucose as substrate may thus find a methodological role in studies of hyperoxia or strategies to optimize perfusion and mitochondrial function. This is the first time that a comparison between glycolysis and the PPP has been carried out directly in the human brain. 
